“…In CIS patients (n=89) who recurred within 12 months after the last BCG treatment, intravesical vicinium resulted in CR rates of 40%, 28%, 17%, and 11% at 3, 6, 12, and 24 months, respectively [ 78 ]. More favorable results were observed for papillary-only tumors (n=38), with recurrence-free rates of 71%, 58%, 50%, and 37% at 3, 6, 12, and 24 months, respectively [ 78 ]. Further, vicinium was well-tolerated with only 52% of patients experiencing treatment-related AEs, the majority being grade 1–2 [ 78 ].…”